To download the full report, click here.

According to a new analysis, in the past two years, commercially insured patients in health plans with value-based contracts for diabetes, high cholesterol and HIV medicines had copays that were, on average, 28 percent lower for those medicines compared to patients in other plans. The data highlight the potential for results-based contracts to reduce health care costs and underscore the need for public policy reforms that allow greater flexibility for innovative payment arrangements that lower out-of-pocket costs and enable patients to access the right treatments the first time. Download the report to learn more.